Abstract: Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that are suitable for cellular labeling or the treatment of cancer. Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds.
Abstract: The present invention relates to methods for treating a disease or disorder associated with EP300 dependency and elevated CRBN expression levels (e.g., cancer (e.g., neuroblastoma)).
Abstract: The present invention is generally directed to identify interacting cells in the tumor microenvironment and using the identified interactions to enhance anti-tumor immunity in cancer. Identified interactions can be modulated using therapeutic agents. Immune cells resistant to suppression can be used for adoptive cell transfer. The present invention is also generally directed to cell types and genes that are correlated to time of tumor growth and tumor size.
Type:
Grant
Filed:
October 5, 2020
Date of Patent:
May 14, 2024
Assignees:
DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Inventors:
Meromit Singer, Aviv Regev, Orit Rozenblatt-Rosen, Davide Mangani, Ana Carrizosa Anderson, Vijay K. Kuchroo, Linglin Huang
Abstract: In some embodiments, a mass spectrometry tag may comprise a linker region, a mass balance region, and a reporter region. The mass spectrometry tag may be configured to fragment in a mass spectrometer via an energy dependent process to produce multiple reporter molecules. For example, the reporter region of the tag may be configured to produce at least two reporter molecules via fragmentation. In some embodiments, one or more regions of the tag may comprise at least one heavy isotope. In some such embodiments, the ability to fragment into multiple reporter molecules as well as the placement and/or number of heavy isotope(s) allows the mass spectrometry tag to be distinguished from other similar mass spectrometry tags. In some such embodiments, the ability to distinguish between tags having the same or substantially similar total mass to charge ratio and reporter region mass may allow the system to have a greater multiplexing capacity than conventional systems.
Type:
Grant
Filed:
July 28, 2021
Date of Patent:
May 14, 2024
Assignees:
President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
Inventors:
Craig Braun, Wilhelm Haas, Steven P. Gygi, Gregory H. Bird, Loren D. Walensky, Martin Helmut Wuhr, Brian K. Erickson
Abstract: The present application is directed to bispecific polypeptides comprising a first domain binding an antigen on an antigen presenting cell (ARC) and a second domain binding an antigen on an immune cell expressing a chimeric antigen receptor (CAR). Nucleic acids, vectors and host cells used in producing the polypeptide of the invention are also disclosed. Compositions comprising the bispecific polypeptides and methods of treating cancer and stimulating activation and expansion of immune cells in vivo and in vitro are also disclosed.
Type:
Application
Filed:
November 13, 2023
Publication date:
May 9, 2024
Applicant:
Peter MacCallum Cancer Institute
Inventors:
Michael Kershaw, Clare Slaney, Bianca Von Scheidt
Abstract: The disclosure provides methods of reprogramming polyclonal T cells to maintain long-term persistence. The disclosure further provides methods of treatment, such as adoptive T cell transfer therapies, that harness Tscms for development of tumor-reactive T cells. In some embodiments, the disclosure provides methods and compositions for positive modulation of the Tscm-producing phenotype, e.g., positive modulation of TCF7 expression. Positive modulation of TCF7 expression allows for maintenance of an increased T number of stem-like T cells capable of both self-renewal and generation of differentiated, cytolytic progeny.
Type:
Application
Filed:
March 1, 2022
Publication date:
May 9, 2024
Applicants:
Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
Abstract: Presented are methods of assessing the teratogenicity of agents by measuring the degradation of SALL4, and related compounds with reduced teratogenicity. Provided herein is a method for assessing the teratogenicity of an agent comprising: contacting an agent with SALL4; and measuring levels of SALL4, wherein the agent is teratogenic if SALL4 levels are substantially reduced in the presence of the agent relative to in the absence of the agent.
Abstract: The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.
Type:
Grant
Filed:
January 20, 2017
Date of Patent:
April 30, 2024
Assignees:
DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventors:
Curtis Huttenhower, Travis Gerke, Christopher Sweeney, Lorelei Mucci, Gwo-Sho Mary Lee, Daniela Bornigen, Xiaodong Wang, Svitlana Tyekucheva, Kristina Jordahl
Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target uPAR and cells comprising such uPAR-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the uPAR-targeted antigen-recognizing receptors for treatment.
Type:
Application
Filed:
December 11, 2023
Publication date:
April 25, 2024
Applicants:
MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
Inventors:
Scott W. Lowe, Michel Sadelain, Corina Amor Vegas, Paul Balderes, Ivo C. Lorenz, Zeda Zhang
Abstract: Described herein are compositions and methods of using single-cell RNA-sequencing to identify treatment resistance in patients with ovarian cancer. Also, described herein are compositions and methods for treatment targeting resistance in patients with ovarian cancer.
Type:
Grant
Filed:
March 30, 2018
Date of Patent:
April 23, 2024
Assignees:
Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc., Massachusetts Institute of Technology
Inventors:
Levi Garraway, Benjamin Izar, Aviv Regev, Orit Rozenblatt-Rosen, Asaf Rotem, Elizabeth Stover, Itay Tirosh
Abstract: Provided herein are STING and SPARCS genes as biomarkers for determining an effective therapy for treating cancer. Further provided are methods for treating cancer using said biomarkers.
Type:
Application
Filed:
December 5, 2023
Publication date:
April 18, 2024
Applicants:
Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
Inventors:
David Barbie, Israel CaƱadas, Shunsuke Kitajima, Thanh Barbie
Abstract: The present invention provides compositions and methods for the treatment or prevention of a neurological disease or disorder of the central nervous system (e.g., a storage disorder, lysosomal storage disorder, neurodegenerative disease, etc.) by reconstitution of brain myeloid cell and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The invention also provides compositions and methods for ablating and reconstituting microglia.
Type:
Grant
Filed:
October 16, 2017
Date of Patent:
April 16, 2024
Assignees:
CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., POLITECNICO DI MILANO, FONDAZIONE TELETHON ETS, DANA-FARBER CANCER INSTITUTE, INC
Abstract: The present invention provides compositions and methods for treating cancers with reduced or absent CDH1 using a RHOA dominant negative polypeptide or biologically active fragment thereof, and/or a nucleic acid encoding a RHOA dominant negative polypeptide or biologically active fragment thereof.
Abstract: Provided herein are nanoparticles which enhance the immunogenicity of antigens for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines, as well as immunogenic compositions comprising the antigen nanoparticles and additional adjuvants for further enhancing immunogenicity.
Type:
Application
Filed:
June 23, 2022
Publication date:
April 11, 2024
Applicants:
Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
Inventors:
Francesco Borriello, Ofer Levy, David J. Dowling, Sirano Dhe-Paganon, Hyuk-Soo Seo
Abstract: It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
Type:
Application
Filed:
January 13, 2022
Publication date:
April 11, 2024
Applicants:
MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITED
Inventors:
John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
Abstract: The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 anti-body-pyrrolodiazepine derivative conjugate using the same.
Type:
Application
Filed:
January 13, 2022
Publication date:
April 11, 2024
Applicants:
MEMORIAL SLOAN KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, DAIICHI SANKYO COMPANY, LIMITED
Inventors:
John T. POIRIER, Charles RUDIN, Jason LEWIS, Abdul KHAN, David ANDREW, Xinlei CHEN, Ivo LORENZ, Hironori MATSUNAGA
Abstract: The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.
Type:
Grant
Filed:
October 20, 2021
Date of Patent:
April 2, 2024
Assignee:
Dana-Farber Cancer Institute, Inc.
Inventors:
John M. Hatcher, Nathanael S. Gray, Jaebong Jang, Dries De Clercq, Pasi Janne, Jamie A. Saxon, Michael Eck, David A. Scott, Alyssa Verano
Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
Type:
Grant
Filed:
February 12, 2021
Date of Patent:
April 2, 2024
Assignees:
THE CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.
Inventors:
James Bradner, Jun Qi, Dennis Buckley, Leonard I. Zon, Elizabeth Macari